Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTA TO STUDY DETERMINE Rx DRUG DEVELOPMENT COSTS

Executive Summary

OTA TO STUDY DETERMINE Rx DRUG DEVELOPMENT COSTS was requested Sept. 30 by House Commerce Committee Chairman Dingell (D-Mich.) and Health Subcommittee Chairman Waxman (D-Calif.). The legislators asked the Office of Technology Assessment to "undertake a study of the cost of researching and developing new prescription drugs." They characterized the study as "a major contribution toward a better understanding of our nation's pharmaceutical industry." While examining health issues and policies under the FD&C Act, Waxman and Dingell noted that "on a number of occasions . . . ranging from orphan drugs to prescription drug price increases to Medicare catastrophic drug coverage, an essential part of the committee's discussion has involved questions about the cost of researching and developing new prescription drugs." However, they continued, "there is little if any objective and reliable data on the R&D costs of new drug development." The Pharmaceutical Manufacturers Association currently says development costs run to $ 125 mil. per drug, a figure that takes into account the R&D costs of compounds that do not reach the marketplace. Individual pharmaceutical company executives have estimated the average drug R&D cost to be closer to $ 90 mil. In a 1987 report on the industry, SRI International estimated drug development costs to be in the $ 50-$ 75 mil. range. "The Rx industry's latest claim of an NCE [new chemical entity] average cost of $ 125 mil. [is] high by $ 50-$ 75 mil.," SRI projected. Dingell and Waxman noted that "there are some independent studies and some industry-developed data" on NCE development costs; however, "all have been severely criticized." Consequently, they said, "the committee's work is impeded by claims of the extremely high R&D costs of new drugs and countervailing criticisms of the accuracy of those claims. These conflicting assertions are constantly repeated, but neither can be verified by the committee."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel